Want to join the conversation?
$AMGN Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 to Sept. 2, 2015 in London. Data will be presented evaluating Repatha(TM) (evolocumab), a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor approved in the European Union
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.